InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,699.94
(
-0.17%
)
US TECH 100
19,261.20
(
-0.09%
)
Dow Jones
42,011.59
(
-0.44%
)
Brent Oil
77.59
(
-0.28%
)
Bitcoin
60,964.83
(
0.35%
)
Post# of 253272
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120524
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 162078

Monday, 06/03/2013 6:40:03 PM

Monday, June 03, 2013 6:40:03 PM

Post# of 253272
PTLA—There’s nothing wrong with Betrixaban per se, but it’s not differentiated from Eliquis (or Xarelto) and it’s very late to market even in the best-case scenario. That’s why MRK pulled out of the partnership to develop Betrixaban two years ago (#msg-61300408).

If PTLA would scrap Betrixaban and focus only on extracting maximum value for PRT-4445, I would be more inclined to invest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up